1. CLINICAL, IMMUNOPHENOTYPIC AND GENETIC CHARACTERISTICS OF AGGRESSIVE (NON‐BURKITT) B‐CELL LYMPHOMA IN A REAL LIFE COHORT. (12th June 2019) Authors: Roulin, L.; Jais, J.; Poullot, E.; Robe, C.; Scherman, E.; Lemonnier, F.; Le Bras, F.; Maarek, A.; Belhadj, K.; Dupuis, J.; Hammoud, M.; El Gnaoui, T.; Mule, S.; Itti, E.; Delfau‐Larue, M.; Gaulard, P.; Haioun, C.; Copie‐Bergman, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE. (23rd June 2022) Authors: Schavgoulidze, A.; Perrot, A.; Cazaubiel, T.; Leleu, X.; Manier, S.; Buisson, L.; Maheo, S.; Do Souto Ferreira, L.; Lannes, R.; Pavageau, L.; Hulin, C.; Marolleau, J.-P.; Voillat, L.; Belhadj, K.; Divoux, M.; Slama, B.; Brechignac, S.; Macro, M.; Stoppa, A.-M.; Sanhes, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 765 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01. (23rd June 2022) Authors: Bobin, A.; Manier, S.; De Keizer, J.; Karlin, L.; Perrot, A.; Hulin, C.; Caillot, D.; Mariette, C.; Lenain, P.; Richez, V.; Tiab, M.; Touzeau, C.; Jaccard, A.; Decaux, O.; Araujo, C.; Belhadj, K.; Benboubker, L.; Déal, C.; Macro, M.; Vincent, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 783 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK. (23rd June 2022) Authors: Kastritis, E.; Minnema, M. C.; Dimopoulos, M. A.; Merlini, G.; Theodorakakou, F.; Fotiou, D.; Huart, A.; Belhadj, K.; Gkolfinopoulos, S.; Manousou, K.; Sonneveld, P.; Palladini, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 805 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY. (23rd June 2022) Authors: Hulin, C.; Macro, M.; Perrot, A.; Royer, B.; Caillot, D.; Belhadj, K.; Frenzel, L.; Benramdane, R.; Demarquette, H.; Bareau, B.; Darre, S.; Calmettes, C.; Le Calloch, R.; Bouketouche, M.; Laribi, K.; Texier, N.; Willaime, M.; Deal, C.; Moreau, P.; Decaux, O. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER. (23rd June 2022) Authors: Macro, M.; Decaux, O.; Perrot, A.; Royer, B.; Chretien, M.; Belhadj, K.; Mohty, M.; Frenzel, L.; Leleu, X.; Dib, M.; Allangba, O.; Zunic, P.; Botoc, I.; Malfuson, J.; Moreau, P.; Garlantazec, R.; Texier, N.; Germain, R.; Deal, C.; Hulin, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 846 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN (R‐GemOx) IN REFRACTORY/RELAPSED (R/R) DLBCL. A REAL LIFE STUDY IN PATIENTS INELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION. (12th June 2019) Authors: Cazelles, C.; Belhadj, K.; Vellemans, H.; Camus, V.; Copi‐Bergman, C.; Veresezan, L.; Itti, E.; Becker, S.; Carvalho, M.; Dupuis, J.; Fabien, L.; Lemonnier, F.; Roulin, L.; El Gnaoui, T.; Jardin, F.; Mounier, N.; Tilly, H.; Haioun, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Rituximab, alkylating agents or combination therapy for gastric mucosa‐associated lymphoid tissue lymphoma: a monocentric non‐randomised observational study. Issue 6 (27th January 2014) Authors: Amiot, A.; Lévy, M.; Copie‐Bergman, C.; Dupuis, J.; Szablewski, V.; Le Baleur, Y.; Baia, M.; Belhadj, K.; Sobhani, I.; Leroy, K.; Haioun, C.; Delchier, J‐C. Journal: Alimentary pharmacology & therapeutics Issue: Volume 39:Issue 6(2014) Page Start: 619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗